Kronos Bio Inc

NASDAQ:KRONUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Kronos Bio, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutics that target the deregulated transcription that causes cancer and other serious diseases. It is developing KB-0742, its internally discovered oral cyclin dependent kinase 9 (CDK9) inhibitor, for the treatment of MYC-amplified and others transcriptionally addicted solid tumors. It has initiated the Phase 2 portion of its Phase 1/2 clinical trial for KB-0742. It is also developing KB-9558, which inhibits the lysine acetyltransferase (KAT) domain of p300, a critical node of the IRF4 TRN. IRF4 is a key transcription factor driver in multiple myeloma and KB-9558 selectively targets its activity. Its scientific focus is on developing medicines that target deregulated transcription, the hallmark of cancer and other serious diseases. Using its Small Molecule Microarray (SMM) platform or other approaches, it can generate and advance small molecule starting points into drug development candidates.

Contact Information

Headquarters

1300 S. El Camino Real, Suite 400SAN MATEO, CA, United States 94402

Phone

650-781-5200

Fax

302-636-5454

Executives

Non-Executive Independent Chairman of the Board

Arie Belldegrun

President, Chief Executive Officer, Director

Norbert Bischofberger

Chief Financial Officer, Chief Operating Officer, Chief Accounting Officer

Deborah Knobelman

Senior Vice President - Corporate Operations and Legal

Allison Frisbee

Senior Vice President - Research and Development

Charles Lin